Aurinia Pharmaceuticals Second Quarter 2024 Earnings Beats Expectations

AUPH Stock  USD 8.98  0.03  0.34%   
Under 59% of all Aurinia Pharmaceuticals' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that some traders are interested. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
  
Aurinia Pharmaceuticals Second Quarter 2024 Results Key Financial Results Revenue US57.2m up 38...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Aurinia Pharmaceuticals Fundamental Analysis

We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Aurinia Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Aurinia Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aurinia Pharmaceuticals Related Equities

BTAIBioXcel Therapeutics   5.71   
0%
100.0%
HEPAHepion Pharmaceuticals   2.04   
0%
35.0%
TERNTerns Pharmaceuticals   1.38   
0%
24.0%
SRPTSarepta Therapeutics   1.21   
0%
21.0%
AKROAkero Therapeutics   1.16   
0%
20.0%
AXSMAxsome Therapeutics   1.10   
0%
19.0%
PTCTPTC Therapeutics   1.08   
0%
18.0%
MDGLMadrigal Pharmaceuticals   0.65   
0%
11.0%
EXELExelixis   0.62   
0%
10.0%
VKTXViking Therapeutics   0.07   
0%
1.0%
TGTXTG Therapeutics   0.31   
5.0%
0%
MCRBSeres Therapeutics   4.17   
73.0%
0%

Complementary Tools for Aurinia Stock analysis

When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon